Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Explore clinical trials studying Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Study availability and eligibility vary by location and protocol.

4 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Refractory Diffuse Large B-Cell Lymphoma (DLBCL) trial results

Recruiting

NCT05836896

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +21 more
Locations: Technische Universität Dresden, NCT/UCC, Early Clinical Trial Unit Dresden, Germany

Completed

NCT01742988

Conditions: Double-expressor Lymphoma (DEL), Double-hit Lymphoma (DHL), Hemic and Lymphatic Diseases, +18 more
Locations: USC/Norris Comprehensive Cancer Center Los Angeles, California, United States

Florida Cancer Specialists Sarasota, Florida, United States

Winship Cancer Institute, Emory University Atlanta, Georgia, United States

University of Chicago Medicine Chicago, Illinois, United States

Active, Not Recruiting

NCT07480850

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, Beijing, China

Active, Not Recruiting

NCT02570542

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: University of Nebraska Medical Center Omaha, Nebraska, United States

Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only) Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Consent and Follow up Only) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Consent and Follow Up Only) Montvale, New Jersey, United States

View all 14 locations